ALK and non-small cell lung carcinoma: In a subsequent randomized phase III trial, KEYNOTE-024, 305 previously-untreated patients with advanced NSCLC having PD-L1 expression in more than 50% tumor cells and no EGFR/ALK mutations were recruited to either receive pembrolizumab or platinum-based chemotherapy (Reck et al., 2016).